Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
BACKGROUND: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM.
METHODS: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non-anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal.
RESULTS: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis.
CONCLUSIONS: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical colorectal cancer - 22(2023), 3 vom: 23. Sept., Seite 267-279 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Chih-Wen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-angiogenesis therapy |
|---|
| Anmerkungen: |
Date Completed 29.08.2023 Date Revised 30.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clcc.2023.03.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356020940 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356020940 | ||
| 003 | DE-627 | ||
| 005 | 20231226065556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clcc.2023.03.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356020940 | ||
| 035 | |a (NLM)37098452 | ||
| 035 | |a (PII)S1533-0028(23)00034-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Chih-Wen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2023 | ||
| 500 | |a Date Revised 30.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM | ||
| 520 | |a METHODS: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non-anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal | ||
| 520 | |a RESULTS: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis | ||
| 520 | |a CONCLUSIONS: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-angiogenesis therapy | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Gene Ontology | |
| 650 | 4 | |a Overall Survival | |
| 700 | 1 | |a Ou, Tao-Shen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wei-Shone |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jeng-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shung-Haur |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Huann-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Shih-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Yuan-Tzu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chun-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Hung-Hsin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Sheng-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Hou-Hsuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yi-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yu-Zu |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Yee |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ling-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Hao-Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical colorectal cancer |d 2000 |g 22(2023), 3 vom: 23. Sept., Seite 267-279 |w (DE-627)NLM122314204 |x 1938-0674 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:3 |g day:23 |g month:09 |g pages:267-279 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clcc.2023.03.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 3 |b 23 |c 09 |h 267-279 | ||